Purchase this article with an account.
B. Gupta, L. Pellosini, N. Patel, S. Jones, S. Sivaprasad; Anti-VEGF Agents for Retinal Angiomatous Proliferans. Invest. Ophthalmol. Vis. Sci. 2009;50(13):733.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The aim of this study is to assess the visual outcomes of patients with RAP treated with ranibizumab.
A retrospective review of case notes of consecutive patients treated with ranibizumab was done. Data collected included baseline vision, time from diagnosis to first treatment, time to re-treatment (2nd injection), mean change in visual acuity, type of treatment, mean number of treatments and mean final visual outcome.
A total of forty one consecutive patients were included. The interval between diagnosis and first treatment ranged from 1 week to 3 months. The mean baseline visual acuity of 42.92 ETDRS letters improved to 51.5 letters. The visual outcome was better in patients with early and small lesions while the outcomes were worse in patients with pigment epithelial detachment (PED). Longitudinal analysis of OCT revealed that subretinal fluid disappeared earlier when compared to intraretinal fluid and pigment epithelial detachment (PED). We also noted that fibrosis was more common in lesions with PED. Two patients developed tear of the retinal pigment epithelium.
The response to ranibizumab depends on the stage of RAP at presentation
This PDF is available to Subscribers Only